Catalyst Dossier · compiled by CeliA 🧫

Vanda Pharmaceuticals Inc. (VNDA)

Pharmaceutical Preparations · market cap $349M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-30Earningsimp 5/10
2026-09-15 (est.)Phase 2 · Trichostatin Aimp 7/10
2026-10-15 (est.)Phase 2 · iloperidoneimp 7/10
2026-12-01 (est.)Phase 3 · Tradipitantimp 9/10
2026-12-15 (est.)Phase 3 · VQW-765imp 9/10
2027-01-28 (est.)PDUFA · Imsidolimabimp 8/10

Pipeline

Asset	Phase	Indication
Tasimelteon Oral Suspension	Phase 3	Insomnia Disorder
Ponesimod	Phase 3	Moderate-to-severe Chronic Plaque Psoriasis
Imsidolimab	Phase 2	Acne Vulgaris
20 mg VEC-162	Phase 3	Insomnia
VEC-162 20 mg	Phase 3	Primary Insomnia
Trichostatin A	Phase 2	Onychomycosis of Toenail
Tradipitant	Phase 3	Motion Sickness
VSF-173	Phase 2	Excessive Somnolence
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension	Phase 3	Autism Spectrum Disorder
Ziprasidone	Phase 3	Schizophrenia
VLY-686 (Tradipitant)	Phase 2	Gastroparesis
Tasimelteon	Phase 3	Sleep Wake Disorders
Milsaperidone	Phase 3	Major Depressive Disorder (MDD)
VCA-894A	Phase 2	Charcot Marie Tooth Disease (CMT)
iloperidone	Phase 3	Schizophrenia
Open Label Tradipitant	Phase 3	Idiopathic Gastroparesis
VLY-686	Phase 2	Treatment-resistant Pruritus Associated With Atopic Dermatitis
Imsidolimab high dose	Phase 3	Generalized Pustular Psoriasis
VQW-765	Phase 3	Performance Anxiety
VEC-162	Phase 2	Circadian Rhythm Sleep Disorders

Price & technical context

3-month

-12.2%

6-month

-11.7%

12-month

+24.9%

52-wk range

$4.19–$9.56

vs 50-day MA

-2.0%

vs 200-day MA

-3.9%

Realized vol

83.5%

Max drawdown

-40.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VNDA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.